Sandetofen Drug Interactions

FC tab: Angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor antagonists: Concomitant use of NSAIDs with ACE inhibitors or angiotensin II receptors antagonists may reduce the blood pressure response to the antihypertensive agent.
Anticoagulant and thrombolytic agents: Concomitant use of this drug and anticoagulant or thrombolytic agents is associated with a higher risk of gastrointestinal bleeding compared with use of either agent alone.
Cardiac glycosides: Concomitant use of this drug and cardiac glycosides may increase plasma concentration of cardiac glycosides.
Diuretics: Patients receiving diuretics may have an increased risk of developing renal failure secondary to decrease renal blood flow resulting from prostaglandin inhibition by NSAIDs. There may also be an increased risk of hyperkalemia with ACE inhibitors and some diuretics, including potassium-sparing diuretics.
Nonsteroidal anti-inflammatory agents: Concomitant use of Aspirin and NSAID increases the risk for serious gastrointestinal effects.
Probenecid: Probenecid delays the excretion of this drug and decreases its extent of protein binding resulting in increased concentrations of this drug in plasma.
Methotrexate: Severe, sometimes fatal, toxicity has occurred following administration of an NSAID, concomitantly with Methotrexate (principally high-dose therapy) in patients with various malignant neoplasms or rheumatoid arthritis. The toxicity was associated with elevated and prolonged blood concentrations of Methotraxate.
Lithium: NSAIDs have been reported to increase serum Lithium concentrations. NSAIDs appear to decrease renal clearance of Lithium.
Quinolones: Convulsion may occur due to an interaction with quinolones.
Zidovudine: There may be increased risk of hematotoxicity if Zidovudine is used with NSAIDs.
Mifepristone: NSAIDs may alter the efficacy of Mifepristone.
Cyclosporine and Tacrolimus: The risk of nephrotoxicity may be increased if the drug given with Cyclosporine or Tacrolimus.
Phenytoin and sulfonylurea antidiabetics: NSAIDs may increase the effects of Phenytoin and sulfonylurea antidiabetics.
Inj: Ulcers and gastrointestinal bleeding may occur in the concomitant use with other NSAIDs, for their synergistic effect.
There may be an increased risk of bleeding and damage to the gastrointestinal mucosa on the concomitant use with anticoagulant drugs, above Heparin prophylaxis dose parenterally, as well as Ticlopidine.
NSAIDs can increase lithium level in the blood until toxic levels, so it needs to be monitored.
On the use of Methotrexate above 15 mg/week or more, NSAIDs may increase Methotrexate toxicity in blood because of clearance through the kidney decreased.
There may be an increase in the toxicity of hydantoins and sulfonamides, if used concomitantly with NSAIDs.
Reduction of antihypertensive effects of diuretics and β-blockers group (keep out as there is no dehydration).
There is an increased risk of bleeding in concomitant use with Pentoxifylline and thrombolytic drugs.
An increase in poisoning of red blood cells (reticulocytes influence) on the concomitant use with Zidovudine.
An increase in hypoglycaemic effect of sulfonylurea class of drugs.
An increase of nephrotoxicity in the use of Cyclosporine and Tacrolimus by NSAIDs. During combination therapy, renal function should be monitored.
An increase in the blood levels of Dexketoprofen on concomitant use with Probenecid.
Cardiac glycosides: NSAIDs may increase blood levels of glycosides.
Mifepristone: NSAIDs should not be used within 8-12 days after Mifepristone use. Because theoretically an inhibitor of prostaglandin synthesis can change the efficacy of Mifepristone.
Quinolone antibiotics: high doses of quinolone and NSAIDs may increase the risk of convulsions.